CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Price, Forecast & Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
CPH.CA Key Statistics, Chart & Performance
The current stock price of CPH.CA is 13.55 CAD. In the past month the price decreased by -4.91%. In the past year, price decreased by -0.88%.
CPH.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.67 | 3.32B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.07B | ||
| CRON.CA | CRONOS GROUP INC | 25.57 | 1.37B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.13 | 846.06M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 603.06M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 602.09M | ||
| HITI.CA | HIGH TIDE INC | N/A | 367.24M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 368.44M | ||
| TSND.CA | TERRASCEND CORP | N/A | 421.50M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 310.30M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 245.92M | ||
| XLY.CA | AUXLY CANNABIS GROUP INC | 5.33 | 215.72M |
Related stock screener links
About CPH.CA
Company Profile
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Company Info
CIPHER PHARMACEUTICALS INC
5750 Explorer Drive,, Suite 404
Mississauga ONTARIO L6H 0M2 CA
CEO: Craig Mull
Employees: 9
Phone: 19056025840
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you describe the business of CIPHER PHARMACEUTICALS INC?
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
What is the stock price of CIPHER PHARMACEUTICALS INC today?
The current stock price of CPH.CA is 13.55 CAD. The price increased by 0.52% in the last trading session.
Does CIPHER PHARMACEUTICALS INC pay dividends?
CPH.CA does not pay a dividend.
How is the ChartMill rating for CIPHER PHARMACEUTICALS INC?
CPH.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for CIPHER PHARMACEUTICALS INC?
CIPHER PHARMACEUTICALS INC (CPH.CA) operates in the Health Care sector and the Pharmaceuticals industry.
What is CIPHER PHARMACEUTICALS INC worth?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a market capitalization of 343.09M CAD. This makes CPH.CA a Small Cap stock.
Who owns CIPHER PHARMACEUTICALS INC?
You can find the ownership structure of CIPHER PHARMACEUTICALS INC (CPH.CA) on the Ownership tab.
CPH.CA Technical Analysis
CPH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CPH.CA. While CPH.CA has a great profitability rating, there are some minor concerns on its financial health.
CPH.CA Financial Highlights
Over the last trailing twelve months CPH.CA reported a non-GAAP Earnings per Share(EPS) of 0.65. The EPS decreased by -48.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.52% | ||
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| Debt/Equity | 0.23 |
CPH.CA Forecast & Estimates
8 analysts have analysed CPH.CA and the average price target is 18.26 CAD. This implies a price increase of 34.75% is expected in the next year compared to the current price of 13.55.
For the next year, analysts expect an EPS growth of 38.33% and a revenue growth 55.59% for CPH.CA